10x Genomics, Inc. TXG recently announced a multi-project research collaboration with Fred Hutchinson Cancer Center to advance single-cell and spatial technologies across solid tumors and blood cancers. The collaboration will focus on biomarker discovery in advanced bladder cancer and residual disease detection in acute myeloid leukemia (AML), marking 10x Genomics’ first clinical research initiative extending into hematologic malignancies.
Per management, cancer care has more effective therapies than ever, but there remains a significant need to better identify which treatments will benefit individual patients. 10x Genomics believes single-cell and spatial biology can provide direct insights into the biology that drives treatment response in tumors and blood, supporting the advancement of precision oncology.
TXG Stock Trend Following the News
Following the announcement, TXG stock lost 5.6% at yesterday’s close. Year to date, the stock skyrocketed 366.6%, outperforming the industry’s 15.9% growth and the S&P 500’s 14.5% gain.
The collaboration could strengthen TXG’s long-term growth opportunity by expanding the use of its technology into clinically relevant applications where precise biological information may improve treatment decisions. Successful research outcomes could increase demand for 10x’s platforms among cancer centers and pharmaceutical researchers while creating additional opportunities for biomarker development and clinical testing. The initiative may also help demonstrate the commercial value of TXG’s technology beyond traditional research applications.
TXG currently has a market capitalization of $10.51 billion.
Image Source: Zacks Investment Research
More on the News
The bladder cancer project will use TXG’s Flex Apex and Xenium platforms, with plans to incorporate Atera, to examine tumor samples from patients receiving antibody-drug conjugates, immune checkpoint inhibitors and other therapies. Researchers will evaluate drug-target expression and tumor-microenvironment characteristics to identify biological markers associated with treatment response and clinical outcomes.
A second project will investigate whether Flex Apex-based single cell analysis can improve residual disease detection in AML. Current monitoring relies on multiple technologies, creating an opportunity for an integrated approach to identifying residual leukemic cells following treatment.
The collaboration also supports 10x Genomics’ broader efforts to build evidence for clinical applications of its single-cell and spatial technologies. Together with the company’s planned CLIA-certified laboratory, the initiative is expected to contribute to a framework for clinical reporting and help define how cellular and spatial data could support treatment planning in oncology and autoimmune disease.
Industry Prospects Favoring the Market
Going by the data provided by Grandview Research, the global single-cell analysis market is estimated to reach $6.5 billion in 2026 and is projected to witness a CAGR of 21.7% through 2033.
Factors like the growing number of drug discovery activities, technological advancements in genomics and cell analysis tools, and rising demand for precision medicine and oncology research are boosting the market’s growth.
Other News
10x Genomics recently announced Sentira, a new cloud-based computational platform designed to simplify and accelerate analysis of single-cell and spatial biology data. Its Sentira Spatial Analysis uses NVIDIA-accelerated computing to reduce processing times from hours to minutes. The platform is currently in early access and is expected to launch commercially in early 2027.
10x Genomics recently began commercial shipments of Atera, its next-generation spatial biology platform designed to combine whole-transcriptome analysis, sub-cellular resolution and single-cell sensitivity at scale. Demand for Atera has exceeded the company’s initial 2026 shipment expectations, with booked orders surpassing 40 instruments.
10x Genomics Price
10x Genomics price | 10x Genomics Quote
TXG’s Zacks Rank & Key Picks
Currently, 10x Genomics carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are OPKO Health OPK, Globus Medical GMED and Merit Medical Systems MMSI.
OPKO Health, currently flaunting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted loss of 1 cent per share, which surpassed the Zacks Consensus Estimate by 87.5%. Revenues of $163.6 million beat the Zacks Consensus Estimate by 24.7%. You can see the complete list of today’s Zacks #1 Rank stocks here.
OPK has an estimated earnings growth rate of 23.3% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 95.1%.
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
Merit Medical Systems, carrying a Zacks Rank #2 at present, reported second-quarter 2026 adjusted EPS of $1.19, which beat the Zacks Consensus Estimate by 23.9%. Revenues of $418.8 million surpassed the Zacks Consensus Estimate by 3.5%.
MMSI has an estimated long-term earnings growth rate of 10.4%. MMSI’s earnings surpassed estimates in the trailing four quarters, the average surprise being 14.1%.
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.
See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
10x Genomics (TXG): Free Stock Analysis Report
Merit Medical Systems, Inc. (MMSI): Free Stock Analysis Report
OPKO Health, Inc. (OPK): Free Stock Analysis Report
Globus Medical, Inc. (GMED): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).